SUBSCRIBE
SUBSCRIBE
Heather McKenzie

Heather McKenzie

Senior Editor

Heather McKenzie is a professional journalist with more than five years experience in the biopharmaceutical industry. Since joining BioSpace, she has written more than 200 features and breaking news articles with a particular focus in neuroscience and gene therapy. She has also traveled internationally to cover global biotech hubs such as Israel. In previous roles, she has covered current affairs, sports, education and politics. She previously spent eight years as a senior content producer for executive-level business conferences in the pharma/biotech, legal, energy and business strategy sectors. In her free time, Heather enjoys creative writing, spending time with family and playing with her energetic Russian Blue cat Roofus. She hails from Toronto and has also lived in Chicago and Chesapeake, Virginia. You can reach her at heather.mckenzie@biospace.com.

Drug Development
Could an Intranasal COVID-19 Vaccine Be More Efficient and Effective Than Traditional Approach?
There are over 170 COVID-19 vaccine candidates at various stages of development, and all but a few of them take the traditional intramuscular approach. But could intranasal delivery ease the logistical nightmare we face in exterminating the pandemic across the globe?
October 5, 2020
 · 
6 min read
 · 
Heather McKenzie
Business
Genentech and Vaccibody Come Together to Develop Cancer Vaccines
“We are very excited to have entered into this transformative agreement that marks the start of a new era for Vaccibody,” Michael Engsig, CEO of Vaccibody, said in a statement.
October 2, 2020
 · 
2 min read
 · 
Heather McKenzie
Alnylam (Pavel Kapysh/Shutterstock)
Drug Development
Alnylam Posts Positive Results of Groundbreaking Phase III PH1 Trial
Alnilam – the bright center star in the middle of Orion’s belt – has navigated its namesake Alnylam to positive results in their ILLUMINATE-B Phase III clinical trial evaluating RNAi therapeutic, lumasiran, in young children with Primary hyperoxaluria Type 1 (PH1).
October 1, 2020
 · 
2 min read
 · 
Heather McKenzie
Policy
CA Governor Looks to Disrupt State’s Generics Market to Promote Affordability
California Gov. Gavin Newsom signed Senate Bill 852 into law on Monday, paving the way for California to manufacture cheaper versions of insulin and other drugs that have been in short supply in recent years.
September 29, 2020
 · 
2 min read
 · 
Heather McKenzie
Business
XtalPi Takes Drug Development into the Next Frontier with $318.8 Million Series C
XtalPi Inc., an AI-based pharmaceutical technology company with an AI-powered platform that twins with existing R&D pipelines, now has $318.8 million more to bring drug development into the future.
September 28, 2020
 · 
2 min read
 · 
Heather McKenzie
Drug Development
BMS a Pioneer in Muscle-Invasive Bladder Cancer with Interim Phase III Opdivo Results
BMS’s ongoing Phase III randomized, double-blind, multi-center study – named CheckMate-274 – compares Opdivo against a placebo in 709 participants deemed to be at a high risk of recurrence after radical surgery.
September 28, 2020
 · 
2 min read
 · 
Heather McKenzie
BioCapital
The Global Cost of Containing COVID-19
Even when a first vaccine is finally approved, much of the developing world currently stands to be left behind, as it was during the 2009 H1N1 pandemic.
September 25, 2020
 · 
5 min read
 · 
Heather McKenzie
Policy
New York Charges J&J with Civil Insurance Fraud in Opioid Industry Probe
Johnson & Johnson has become the next big pharma player to be accused in New York State’s Department of Financial Services opioid industry probe.
September 17, 2020
 · 
2 min read
 · 
Heather McKenzie
Business
Cidara Therapeutics Aims to Prevent Future COVID-19/Flu Season ‘Twindemics’
Cidara Therapeutics is hoping that its novel approach to influenza will prevent future “twindemic” double threats like the one we may face this year.
September 17, 2020
 · 
5 min read
 · 
Heather McKenzie
Biotech Bay
Hexagon Bio to Move into Clinic with $47 Million in Series A Financing
Hexagon Bio, a California-based biotechnology company turning nature’s DNA into medicines for cancers and infectious diseases with unmet needs, will move into clinical research with $47 million in Series A financing.
September 16, 2020
 · 
2 min read
 · 
Heather McKenzie
Business
Investors Pump $30 Million into Orasis Pharmaceuticals’ Series C Financing Round
Orasis Pharmaceuticals has closed on $30 million dollars in Series C financing that will propel its corrective eye drop candidate for presbyopia symptoms, CSF-1, through Phase III clinical trials.
September 11, 2020
 · 
2 min read
 · 
Heather McKenzie
Celyad’s High Hopes for a Path Forward in Cancer Immunotherapy with CYAD-211
Celyad Oncology is at the forefront of cutting-edge immunotherapy and is hopeful of providing a new way forward for patients with relapsed/refractory multiple myeloma.
September 2, 2020
 · 
5 min read
 · 
Heather McKenzie
Load More